Eli Lilly (NYSE: LLY) has been on a roll in recent years, thanks to its leadership in the weight management drug market.
Pharmaceutical Technology on MSN
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.
Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be ...
Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Eli Lilly is in advanced talks to buy Ventyx Biosciences for more than $1 billion, the Wall Street Journal reported on ...
The about-$1 billion deal could come imminently.
MarketBeat on MSN
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...
Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients ...
Ventyx Biosciences stock surged 62% after reports Eli Lilly is in talks to acquire the biotech firm for over $1B. Deal could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback